$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...
Hence then, the article about atossa therapeutics announces closing of registered direct offering of up to 16 5 million in gross proceeds was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds )
Also on site :
- Elon Musk’s Exes Reveal His ‘Assembly Line’ Approach to Having Kids in New Documentary: ‘Somebody on Elon’s Side Referred to Us as “the Breeders”’
- Carson Kressley Just Mic-Dropped Vicki Gunvalson’s ‘RHOC’ Motor Boating Outfit and the Internet Can’t Stop Screaming
- Brad Bird’s ‘Ray Gunn,’ ‘Toy Story 5’ and Roger Deakins Lead View Conference Lineup as AI Debate Takes Center Stage